577 results
6-K
EX-99.2
SNY
Sanofi
2 May 24
Current report (foreign)
3:52pm
-blind treatment period, followed by a 28-week open-label treatment, and then a 4-week safety follow-up or long-term extension period. The adolescent
6-K
EX-99.1
SNY
Sanofi
25 Apr 24
Sales growth of 6.7% at CER and business EPS(1) of €1.78
10:49am
2 long-term extension study of Nexviazyme in pediatric patients with infantile-onset Pompe disease (IOPD), suggested that it meaningfully improved …
Acquisitions of intangibles assets, investments and other long-term financial assets (1)
Restructuring costs and similar items paid
Proceeds from disposals
F-3ASR
SNY
Sanofi
4 Apr 24
Automatic shelf registration (foreign)
2:07pm
will be capital gain or loss. The gain or loss on the sale, exchange or retirement of a debt security will be long-term capital gain or loss if you have held … the debt security for more than one year on the date of disposition. Under current law, net long- term capital gain recognized by an individual U.S. holder
F-3ASR
EX-1.1
SNY
Sanofi
4 Apr 24
Automatic shelf registration (foreign)
2:07pm
or any other long term debt securities of the Company by Moody’s Investors Services, Inc., Standard & Poor’s Ratings Services and Scope Ratings GmbH … rating of the Securities or of any other long term debt securities of the Company (other than an announcement with positive implications of a possible
F-3ASR
EX-25.1
SNY
Sanofi
4 Apr 24
Automatic shelf registration (foreign)
2:07pm
)
K654
6. Holdings of long-term unsecured debt issued by other FDIC-insured depository institutions
K655
7. Unsecured “Other borrowings” with a remaining
6-K
EX-99.2
9epbqy4d6isel88pb8q
2 Feb 24
Approval based on Phase 3 EoE KIDS trial showing a greater proportion of children taking Dupixent achieved histological remission compared to placebo
1:21pm
6-K
EX-99.1
qt4zf9g
1 Feb 24
Sanofi Delivers Solid Sales and Business EPS Growth at CER Amidst Successful Product Launches and Advancements in Immunology Pipeline
9:45am
6-K
EX-99.3
z0ad38 3udf2t1i5z
20 Dec 23
Current report (foreign)
10:39am
6-K
EX-99.1
rqb 749mzoetg7n7pj2f
20 Dec 23
Current report (foreign)
10:39am
6-K
EX-99.1
f3c3k8fxkobqamzs4
27 Oct 23
Specialty Care growth, strong launch uptake of Beyfortus® and ALTUVIIIO® drive solid Q3 results
12:39pm
6-K
EX-99.1
llpszrxi8yg
27 Oct 23
Sanofi Enters Next Chapter of Play to Win Strategy
11:33am
6-K
EX-99.3
w3xq5luy1uyy29v
20 Oct 23
Late-breaking amlitelimab Phase 2b data presented at EADV show potential best-in-class profile in atopic dermatitis
2:31pm
6-K
EX-99.1
szdtl4jw96 wiqjqgf
27 Sep 23
Current report (foreign)
6:06am
6-K
EX-99.1
amsdbs6lg2a98l7
28 Jul 23
Solid Q2 performance and strong pipeline momentum
3:35pm
6-K
EX-99.1
44shuc fof1
28 Jul 23
Sanofi to acquire Qunol®, a fast-growing U.S. brand in the healthy aging segment
9:18am
6-K
EX-99.2
pltzxphk2mcg7ybxtj70
28 Jul 23
Condensed Half-year Consolidated Financial Statements
7:00am
6-K
EX-99.1
0dew2a9rfjel1k
28 Jul 23
Condensed Half-year Consolidated Financial Statements
7:00am
6-K
EX-99.3
74oo63ova0qat3t 6wl9
2 Jun 23
Approval of the financial statements for the fiscal year 2022
10:53am
6-K
EX-99.1
5v6d5o
27 Apr 23
Strong Q1 growth driven by Specialty Care, Vaccines and CHC
11:39am
6-K
EX-99.1
2r50jvsa r3qvr
20 Dec 22
Dupixent® (dupilumab) approved by European Commission as the first and only targeted medicine indicated for prurigo nodularis
6:13am